Table 4. Bendamustine in phase I (/II) studies.

Author	Phase	n	Bendamustine regimen	MTD/RD (mg m−2)	DI (mg m−2 week−1)	DLT
Schöffski et al	I	19	d1, d8 q 4 weeks	160/140	80	Mouth dryness, fatigue
Schöffski et al	I	12	Weekly × 8	80/60	60	Mouth dryness, fatigue, fever
Rasschaert et al	I	23	d1 q 3 weeks	280/260	87	Fatigue, cardiac toxicity
Bergmann et al CLL	I/II	16	d1, d2 q 3–4 weeks	80/70	47–35	Granulocytopaenia, infection
Lissichkov et al CLL	I/II	15	d1, d2 q 3–4 weeks	110/100	50	Bilirubinaemia Diarrhoea
Present study	I	15	d1, d2 q3 weeks	180/160	107	Thrombocytopaenia